A Study of Nimotuzumab Plus Concurrent Chemoradiotherapy Sequential Maintenance Treatment for Cervical Carcinoma

A Multicentre, Prospective, Randomized, Double-blind, Placebo-controlled Study of Nimotuzumab Plus Concurrent Chemoradiotherapy Sequential Maintenance Treatment for Locally Advanced Cervical Squamous Cell Carcinoma

The purpose of this study is to evaluate the efficacy and safety of nimotuzumab plus concurrent chemoradiotherapy sequential maintenance therapy versus placebo combined with concurrent chemoradiotherapy in patients with locally advanced cervical squamous cell carcinoma.

The primary hypotheses are that nimotuzumab plus concurrent chemoradiotherapy sequential maintenance therapy is superior to placebo plus concurrent chemoradiotherapy with respect to progression-free survival.

Study Overview

• Status: Not yet recruiting
• Conditions: Cervical Cancer
• Intervention / Treatment: Radiation: Brachytherapy; Biological: Nimotuzumab; Drug: Cisplatin; Radiation: External Beam Radiotherapy (EBRT); Drug: placebo for Nimotuzumab

Detailed Description

This is a multicenter, prospective, randomized, double-blind, placebo-controlled clinical study.The trail will enroll 460 subjects (FIGO 2018, stageIB3-IVA)who meet enrollment criteria but do not meet exclusion criteria. According to clinical stage (FIGO 2018 stage, stage IB3-IIB or III-IVA) 、tumor diameter (>4cm or ≤4cm)、 age (≥18 years and < 65 years old or ≥65 years old and ≤80 years old) for stratified randomization. They are divided into experimental group and control group according to 1:1. Patients in the experimental group will receive nimotuzumab 400mg on the basis of concurrent chemoradiotherapy, once a week for 7-8 weeks, and then maintenance treatment once every 2 weeks for 24 weeks. Using placebo(Nimotuzumab injection mimics) in the control group 80 ml on the basis of concurrent chemoradiotherapy, once a week for 7 to 8 weeks, after the maintenance treatment, once every 2 weeks for 24 weeks. Patients with incomplete tumor response assessed by imaging and pathological examination 3 months after radiotherapy can be given 2-4 cycles of adjuvant chemotherapy with cisplatin/carboplatin combined with paclitaxel regimen. Regular imaging examination and survival follow-up were performed after treatment. The primary efficacy end point was progression-free survival.

• Study Type: Interventional
• Enrollment (Estimated): 460
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: Ping Jiang; Phone Number: 13439796018; Email: drjiangping@qq.com
• Study Contact Backup: Name: Junjie Wang; Phone Number: 13701076310; Email: junjiewang_edu@sina.cn

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• 1.Aged 18-80 years old;
• 2.Histologically diagnosed primary cervical squamous cell carcinoma, with clinical stage IB3-IVA (FIGO 2018);
• 3.At least one measurable lesion according to RECIST 1.1;
• 4.Absence of severe hematopoietic dysfunction and heart, lung, liver, kidney dysfunction and immunodeficiency, laboratory test results meet the following criteria: Hemoglobin ≥ 90 g/L; Absolute neutrophil count ≥ 1.5 × 10^9/L and white blood cell count ≥ 3.0 × 10^9/L; Platelet count ≥ 100 × 10^9/L; Aspartate aminotransferase (AST) ≤ 2.5 × ULN; Alanine aminotransferase (ALT) ≤ 2.5 × ULN ; Total bilirubin ≤ 1.5 × ULN; Serum creatinine ≤ 1.0 × ULN;
• 5.ECOG score 0-1 points;
• 6.Women of childbearing potential must have a negative serum or urine HCG within 72 hours prior to enrollment (postmenopausal women must have been amenorrheic for at least 12 months to be considered of non-childbearing potential. A pregnancy test is not required for women who have demonstrated tubal ligation); Women of childbearing potential who are willing to take medically recognized contraceptive measures during the trial;
• 7.Compliance is good and informed consent is voluntarily signed.

Exclusion Criteria:

• 1.Cervical adenocarcinoma and rare pathological types of malignant tumors;
• 2.Previous surgery for cervical cancer, pelvic radiation therapy, systemic chemotherapy, tumor targeted therapy, immunotherapy;
• 3.Ureteral obstruction, inability to place ureteral stent or pyelostomy;
• 4.Pregnant or lactating women;
• 5.Patients with rectovaginal fistula/vaginovesical fistula/uncontrolled vaginal bleeding or at risk of fistula;
• 6.Had undergone major surgery (except biopsy) within 4 weeks prior to randomization;
• 7.Had received a live vaccine within 4 weeks prior to the initial study drug treatment or planned to vaccinate during the study;
• 8.Human immunodeficiency virus (HIV) infection;Active hepatitis B (the quantitative detection result of HBV DNA exceeds the lower limit of detection), or HCV infection (the quantitative detection result of HCV RNA exceeds the lower limit of detection);
• 9.Had the following serious medical conditions: a) Uncontrolled hypertension (defined as systolic blood pressure > 150 mmHg or diastolic blood pressure > 100 mmHg), or had experienced a hypertensive crisis; b) Myocardial infarction and unstable angina occurred within 6 months before randomization; c) Decompensated heart failure within three months before enrollment (NYHA class III and IV); d) The presence of severe arrhythmias requiring long-term medical intervention, except in patients with asymptomatic atrial fibrillation with stable ventricular rate; e) Left ventricular ejection fraction (LVEF)<50%; f) The presence of uncontrolled hyperglycemia; g) The presence of uncontrollable infections；
• 10.The presence of active or suspected autoimmune diseases, except for type 1 diabetes、hypothyroidism or skin conditions that do not require systemic treatment (vitiligo、psoriasis or alopecia)；
• 11.Conditions requiring systemic treatment with corticosteroids or other immunosuppressive agents within 14 days before randomization；
• 12.Patients with a history of other malignant tumors (except cured cutaneous basal cell carcinoma);
• 13.Patients with Crohn's disease and ulcerative colitis;
• 14.Patients who are participating in other clinical trials or have stopped clinical trials for less than 4 weeks;
• 15.Patients with known hypersensitivity to Nimotuzumab or its components;
• 16.Patients with contraindications to cisplatin、carboplatin and paclitaxel;
• 17.Patients with neurological or psychiatric disorders affecting cognitive ability;
• 18.Patients whose lesions cannot be treated with intracavitary radiotherapy as assessed by the investigator;
• 19.Any condition that, in the opinion of the Investigator, may be inappropriate for patients in the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Nimotuzumab+chemoradiotherapy; Participants receive Nimotuzumab 400 mg intravenously (IV) on Day 1 of each week cycle (QW) for 7-8 cycles followed by Nimotuzumab 400 mg IV on Day 1 of each 2-week cycle (Q2W) for an additional 12 cycles. During the QW dosing period of Nimotuzumab, participants receive concurrent chemoradiotherapy. The standard of care chemoradiotherapy regimen includes cisplatin 40 mg/m^2 IV once or divides into 3 times per week (QW) for 4 or 5 weeks plus external beam radiotherapy (EBRT) followed by brachytherapy with minimum total radiotherapy dose of 80-85 Gray Units (Gy) for volume-directed given with the total duration of radiation treatment not to exceed 8 weeks .	Radiation: Brachytherapy; Brachytherapy; Biological: Nimotuzumab; Nimotuzumab 400mg; Drug: Cisplatin; Cisplatin 40mg/m^2; Radiation: External Beam Radiotherapy (EBRT); External Beam Radiotherapy (EBRT)
Experimental: placebo for Nimotuzumab+chemoradiotherapy; Participants receive placebo for Nimotuzumab 400 mg intravenously (IV) on Day 1 of each week cycle (QW) for 7-8 cycles followed by placebo 400 mg IV on Day 1 of each 2-week cycle (Q2W) for an additional 12 cycles. During the QW dosing period of placebo, participants receive concurrent chemoradiotherapy. The standard of care chemoradiotherapy regimen includes cisplatin 40 mg/m^2 IV once or divides into 3 times per week (QW) for 4 or 5 weeks plus external beam radiotherapy (EBRT) followed by brachytherapy with minimum total radiotherapy dose of 80-85 Gray Units (Gy) for volume-directed given with the total duration of radiation treatment not to exceed 8 weeks .	Radiation: Brachytherapy; Brachytherapy; Drug: Cisplatin; Cisplatin 40mg/m^2; Radiation: External Beam Radiotherapy (EBRT); External Beam Radiotherapy (EBRT); Drug: placebo for Nimotuzumab; placebo for Nimotuzumab 400mg; Other Names: placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed Blinded Independent Central Review (BICR)	PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first.	Up to approximately 5 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by by the Investigator	PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first.	Up to approximately 5 years
3-,5-Year Overall Survival (OS)	OS is the time from randomization to death due to any cause.	Up to approximately 3 and 5 years
3-,5-Year Disease Free Survival(DFS)	DFS is defined as the time from randomization to disease recurrence or death due to any cause.	Up to approximately 3 and 5 years
3-,5-Year Locoregional Recurrence-Free Survival(LRRFS)	Locoregional recurrence-free survival (LRRFS) was defined as the absence of either consistent or relapsed disease at the primary tumor site or the regional lymph nodes	Up to approximately 3 and 5 years
3-,5-Year Distant Metastasis-free Survival (DMFS)	Distant metastasis-free survival (DMFS) was calculated from the date of patient recruitment to the date of distant metastasis.	Up to approximately 3 and 5 years
Tumor Regression Rate(TRR)	The maximum diameter represents the size of the tumor by MRI. Tumor size for each patient were obtained: pre-RT tumor size (V1), pre- brachytherapy tumor size (V2). TRR=(V1-V2)/V1 × 100%.	From date of randomization until the date of brachytherapy,assessed up to 5 weeks
Complete Response Rate	The proportion of subjects with the best complete response in this group assessed by MRI.	From date of randomization until the date of brachytherapy,assessed up to 5 weeks
Complete Response Rate	The proportion of subjects with the best complete response in this group assessed by MRI.	3 months later after treatment
Objective Response Rate	The proportion of subjects with the best complete response or partial response in this group assessed by MRI.	3 months later after treatment
Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status Score	The EORTC QLQ-C30 is a questionnaire that rates the overall quality of life in cancer participants. The first 28 questions use a 4-point scale (1=not at all to 4=very much) for evaluating function (physical, role, social, cognitive, emotional), symptoms (diarrhea, fatigue, dyspnea, appetite loss, insomnia, nausea/vomiting, constipation, and pain) and financial difficulties. The last 2 questions use a 7-point scale (1=very poor to 7=excellent) to evaluate overall health and quality of life. Global scores are converted to a score of 0 to 100, with a higher score indicating improved health status. The change from baseline in EORTC QLQ-C30 score will be presented.	Baseline and up to approximately 5 years
Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Symptom Specific Scale for Cervical Cancer (EORTC QLQ-CX24) Score	The EORTC QLQ-CX24 is a questionnaire that rates the symptoms common to women with cervical cancer and evaluates the impact of disease and/or treatments. The 24 items use a 4-point scale (1=not at all to 4=very much) and are classified into 3 multi-item scales, 11 items with symptom experience, 3 items with body image, and 4 items with sexual/ vaginal functioning. The other items of the questionnaire are lymphedema, peripheral neuropathy, menopausal symptom, sexual worry, sexual activity, and sexual enjoyment. The change from baseline in EORTC QLQ-CX24 score will be presented.	Baseline and up to approximately 5 years
Incidence of Treatment-Emergent Adverse Events	Safety was assessed as adverse events during treatment, the incidence of various adverse events such as adverse events related to the study drug during treatment, laboratory tests, etc	Within 30 days from the start of treatment to the end of the last treatment

Collaborators and Investigators

• Sponsor: Biotech Pharmaceutical Co., Ltd.
• Investigators: Study Chair: Junjie Wang, Peking University Third Hospital; Study Chair: Lichun Wei, TThe First Affiliated Hospital，the Air Force Medical University; Study Chair: Lijuan Zou, The Second Affiliated Hospital of Dalian Medical University; Study Chair: Zi Liu, First Affiliated Hospital Xi'an Jiaotong University; Study Chair: Jiayi Chen, Ruijin Hospital; Study Chair: Huijun Cheng, Henan Cancer Hospital; Study Chair: Rutie Yin, West China Second University Hospital; Study Chair: Xiangkun Yuan, Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine.HeBei; Study Chair: Hui Qiu, Wuhan University Zhongnan Hospital; Study Chair: Hong Zhu, Xiangya Hospital of Central South University; Study Chair: Tiejun Wang, The Second Norman Bethune Hospital of Jilin University; Study Chair: Xiaomei Fan, The Fourth Hospital of Hebei Medical University Hebei Tumor Hospital; Study Chair: Keqiang Zhang, Hunan Cancer Hospital; Study Chair: Dihong Tang, Hunan Cancer Hospital; Study Chair: Qiongyu Lan, Second Affiliated Hospital of Nanchang University; Study Chair: Xiaoying Xue, The Second Hospital of Hebei Medical University; Study Chair: Song Gao, Shengjing Hospital; Study Chair: Guang Li, First Hospital of China Medical University; Study Chair: Qiuhong Tian, The First Affiliated Hospital of Nanchang University; Study Chair: Guoqing Wang, Shanxi Provincial Cancer Hospital; Study Chair: Dong Qian, The First Affiliated Hospital of USTC (Anhui Provincial Hospital); Study Chair: Manbo Cai, The First Affiliated Hospital of University of South China; Study Chair: Yuhua Gao, Liaoning cancer Hospital & Institute; Study Chair: Dehua Wu, Nanfang Hospital, Southern Medical University; Study Chair: Xiaoge Sun, The Affiliated Hospital of Inner Mongolia Medical University; Study Chair: Yunyan Zhang, Cancer Hospital Affiliated to Harbin Medical University; Study Chair: Kun Gao, Guangxi Medical University Cancer Center; Study Chair: Qin Lin, The First Affiliated hospital of Xiamen University; Study Chair: Qin Xu, Fujian Cancer Hospital; Study Chair: Hao Yang, Peking University Cancer Hospital Inner Mongolia Hospital; Study Chair: Rong Huang, First People's Hospital of Foshan; Study Chair: Xianming Li, Shenzhen People's Hospital; Study Chair: Juntao Ran, LanZhou University; Study Chair: Xiaojie Ma, Affiliated Hospital of North Sichuan Medical College; Study Chair: Xingrao Wu, Yunnan Cancer Hospital; Study Chair: Yipeng Song, Yantai Yuhuangding Hospital; Study Chair: Jun Wang, Tianjin Cancer Hospital Airport Hospital; Study Chair: Dapeng Li, Shandong Cancer Hospital & Institute; Study Chair: Siyuan Zeng, Jiangxi Maternal and Child Health Hospital; Study Chair: Hongyun Shi, Affiliated Hospital of Hebei University; Study Chair: Weihu Wang, Peking University Cancer Hospital & Institute; Study Chair: Jidong Zhang, Shanxi Province Cancer Hospital

Study record dates

Study Major Dates

• Study Start (Estimated): April 1, 2024
• Primary Completion (Estimated): April 1, 2030
• Study Completion (Estimated): April 1, 2030

Study Registration Dates

• First Submitted: February 9, 2023
• First Submitted That Met QC Criteria: March 20, 2024
• First Posted (Actual): March 27, 2024

Study Record Updates

• Last Update Posted (Actual): March 27, 2024
• Last Update Submitted That Met QC Criteria: March 20, 2024
• Last Verified: March 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms by Histologic Type; Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Neoplasms, Glandular and Epithelial; Uterine Neoplasms; Genital Neoplasms, Female; Uterine Cervical Diseases; Uterine Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Diseases; Genital Diseases, Female; Uterine Cervical Neoplasms; Carcinoma; Antineoplastic Agents; Antineoplastic Agents, Immunological; Nimotuzumab
• Other Study ID Numbers: BPL-Nim-CC-3003

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No